Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Psychiatric Quarterly
Published in: Psychiatric Quarterly 1/2018

01-03-2018 | Review Article

Clozapine in Reducing Aggression and Violence in Forensic Populations

Authors: Kathleen Patchan, Gopal Vyas, Ann L. Hackman, Marie Mackowick, Charles M. Richardson, Raymond C. Love, Ikwunga Wonodi, MacKenzie A. Sayer, Matthew Glassman, Stephanie Feldman, Deanna L. Kelly

Published in: Psychiatric Quarterly | Issue 1/2018

Login to get access

Abstract

Popular media often portray people with a mental illness as being aggressive, violent, and incarcerated as a result of their behavior. Despite exaggeration in the media, risks for some aggressive behaviors are in fact higher in individuals with schizophrenia. This is often the case with influence of comorbid substance use disorders. It is essential that mental health professionals are aware of treatments that may help with attenuating and treating behaviors that contribute to violence, aggression and incarceration. This paper reviews violence and incarceration in individuals with schizophrenia as well as recommendations, guidelines and benefits for the use of clozapine in this population. Clozapine remains one of the most underutilized evidence-based medications available in the psychiatric arena in the United States. It is a viable and recommended option in the forensic population and it may be helpful on the path to recovery as well as bring substantial savings to the criminal justice system.
Literature
1.
Bortolato, B, Miskowiak, KW, Kohler, CA, et al. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. Neuropsychiatr Dis Treat 2015;11:3111–3125.PubMedPubMedCentral
2.
Carbon, M and Correll, CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr 2014;19 Suppl 1:38–52; quiz 35–37, 53.PubMed
3.
Lysaker, PH, Vohs, J, Minor, KS, et al. Metacognitive Deficits in Schizophrenia: Presence and Associations With Psychosocial Outcomes. J Nerv Ment Dis 2015;203:530–536.CrossRefPubMed
4.
Bouwmans, C, de Sonneville, C, Mulder, CL, et al. Employment and the associated impact on quality of life in people diagnosed with schizophrenia. Neuropsychiatr Dis Treat 2015;11:2125–2142.PubMedPubMedCentral
5.
Brekke, JS, Prindle, C, Bae, SW, et al. Risks for individuals with schizophrenia who are living in the community. Psychiatr Serv 2001;52:1358–1366.CrossRefPubMed
6.
Latalova, K, Kamaradova, D, and Prasko, J. Violent victimization of adult patients with severe mental illness: a systematic review. Neuropsychiatr Dis Treat 2014;10:1925–1939.CrossRefPubMedPubMedCentral
7.
8.
Regier, DA, Farmer, ME, Rae, DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511–2518.CrossRefPubMed
9.
Mueser, KT, Penn, DL, Addington, J, et al. The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components. Psychiatr Serv 2015;66:680–690.CrossRefPubMedPubMedCentral
10.
Dixon, LB, Goldman, HH, Bennett, ME, et al. Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatr Serv 2015;66:691–698.CrossRefPubMedPubMedCentral
11.
12.
Weinstein, H, Kim, D, Mack, A, et al. Prevalence and assessment of mental disorders in correctional settings. Handbook of correctional mental health 2005;43–68.
13.
James, D and Glaze, L. Mental health problems of prison and jail inmates (Bureau of Justice Statistics Special Report, NCJ 213600). Washington, DC: Department of Justice 2006;
14.
Soyka, M, Morhart-Klute, V, and Schoech, H. Delinquency and criminal offenses in former schizophrenic inpatients 7–12 years following discharge. Eur Arch Psychiatry Clin Neurosci 2004;254:289–294.CrossRefPubMed
15.
Ghoreishi, A, Kabootvand, S, Zangani, E, et al. Prevalence and attributes of criminality in patients with schizophrenia. J Inj Violence Res 2015;7:7–12.PubMedPubMedCentral
16.
Ascher-Svanum, H, Nyhuis, AW, Faries, DE, et al. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia. BMC Psychiatry 2010;10:11.CrossRefPubMedPubMedCentral
17.
Greenberg, G, Rosenheck, RA, Erickson, SK, et al. Criminal justice system involvement among people with schizophrenia. Community Ment Health J 2011;47:727–736.CrossRefPubMed
18.
Baillargeon, J, Binswanger, IA, Penn, JV, et al. Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry 2009;166:103–109.CrossRefPubMed
19.
Steadman, HJ, Osher, FC, Robbins, PC, et al. Prevalence of serious mental illness among jail inmates. Psychiatr Serv 2009;60:761–765.CrossRefPubMed
20.
Fazel, S and Danesh, J. Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet 2002;359:545–550.CrossRefPubMed
21.
Hawthorne, WB, Folsom, DP, Sommerfeld, DH, et al. Incarceration among adults who are in the public mental health system: rates, risk factors, and short-term outcomes. Psychiatr Serv 2012;63:26–32.CrossRefPubMed
22.
Lin, I, Muser, E, Munsell, M, et al. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. J Med Econ 2015;18:219–229.CrossRefPubMed
23.
Robertson, AG, Swanson, JW, Frisman, LK, et al. Patterns of justice involvement among adults with schizophrenia and bipolar disorder: key risk factors. Psychiatr Serv 2014;65:931–938.CrossRefPubMed
24.
Robertson, AG, Swanson, JW, Lin, H, et al. Influence of Criminal Justice Involvement and Psychiatric Diagnoses on Treatment Costs Among Adults With Serious Mental Illness. Psychiatr Serv 2015;66:907–909.CrossRefPubMedPubMedCentral
25.
26.
Kane, J, Honigfeld, G, Singer, J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796.CrossRefPubMed
27.
Wahlbeck, K, Cheine, M, Essali, A, et al. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156:990–999.PubMed
28.
Chakos, M, Lieberman, J, Hoffman, E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518–526.CrossRefPubMed
29.
Tuunainen, A, Wahlbeck, K, and Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1–10.CrossRefPubMed
30.
31.
Citrome, L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 2012;13:1545–1573.CrossRefPubMed
32.
Leucht, S, Cipriani, A, Spineli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951–962.CrossRefPubMed
33.
Frogley, C, Taylor, D, Dickens, G, et al. A systematic review of the evidence of clozapine's anti-aggressive effects. Int J Neuropsychopharmacol 2012;15:1351–1371.CrossRefPubMed
34.
Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001;52:1510–1514.CrossRefPubMed
35.
Volavka, J, Czobor, P, Sheitman, B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255–262.CrossRefPubMed
36.
Krakowski, MI, Czobor, P, and Nolan, KA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol 2008;28:485–493.CrossRefPubMed
37.
Victoroff, J, Coburn, K, Reeve, A, et al. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci 2014;26:283–312.CrossRefPubMed
38.
Buchanan, RW, Kreyenbuhl, J, Kelly, DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71–93.CrossRefPubMed
39.
Stone-Brown, K, Naji, M, Francioni, A, et al. Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. CNS Spectr 2016;21:60–69.CrossRefPubMed
40.
Qurashi, I, Stephenson, P, Chu, S, et al. An evaluation of subjective experiences, effects and overall satisfaction with clozapine treatment in a UK forensic service. Ther Adv Psychopharmacol 2015;5:146–150.CrossRefPubMedPubMedCentral
41.
Smith, H and White, T. The effect of clozapine on the social behaviour schedule in patients attending a forensic psychiatry day hospital. Med Sci Law 2004;44:213–216.CrossRefPubMed
42.
Buscema, CA, Abbasi, QA, Barry, DJ, et al. An algorithm for the treatment of schizophrenia in the correctional setting: the Forensic Algorithm Project. J Clin Psychiatry 2000;61:767–783.CrossRefPubMed
43.
Martin, A, O'Driscoll, C, and Samuels, A. Clozapine use in a forensic population in a New South Wales prison hospital. Aust N Z J Psychiatry 2008;42:141–146.CrossRefPubMed
44.
Ronaldson, KJ, Fitzgerald, PB, and McNeil, JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015;132:231–240.CrossRefPubMed
45.
Alawami, M, Wasywich, C, Cicovic, A, et al. A systematic review of clozapine induced cardiomyopathy. Int J Cardiol 2014;176:315–320.CrossRefPubMed
46.
Williams, AM and Park, SH. Seizure associated with clozapine: incidence, etiology, and management. CNS Drugs 2015;29:101–111.CrossRefPubMed
47.
Honigfeld, G, Arellano, F, Sethi, J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998;59 Suppl 3:3–7.PubMed
48.
Munro, J, O'Sullivan, D, Andrews, C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. The British Journal of Psychiatry 1999;175:576–580.CrossRefPubMed
49.
Lahdelma, L and Appelberg, B. Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted. J Clin Psychiatry 2012;73:837–842.CrossRefPubMed
50.
Drew, L. Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry 2013;21:335–337.CrossRefPubMed
51.
Balda, MV, Garay, OU, Papale, RM, et al. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012). Int Clin Psychopharmacol 2015;30:109–114.CrossRefPubMed
52.
Ikai, S, Suzuki, T, Uchida, H, et al. Reintroduction of clozapine after perforation of the large intestine--a case report and review of the literature. Ann Pharmacother 2013;47:e31.CrossRefPubMed
53.
Kelly, DL, Ben-Yoav, H, Payne, GF, et al. Blood Draw Barriers for Treatment with Clozapine and Development of Point-of-Care Monitoring Device. Clin Schizophr Relat Psychoses 2015;
54.
Gee, S, Vergunst, F, Howes, O, et al. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16–24.CrossRefPubMed
55.
Tungaraza, TE and Farooq, S. Clozapine prescribing in the UK: views and experience of consultant psychiatrists. Ther Adv Psychopharmacol 2015;5:88–96.CrossRefPubMedPubMedCentral
56.
57.
Hill, M and Freudenreich, O. Clozapine: key discussion points for prescribers. Clin Schizophr Relat Psychoses 2013;6:177–185.CrossRefPubMed
58.
Citrome, L and Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs 2011;25:1009–1021.CrossRefPubMed
59.
Kelly, DL, Dixon, LB, Kreyenbuhl, JA, et al. Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. J Clin Psychiatry 2006;67:1404–1411.CrossRefPubMed
60.
Mallinger, JB, Fisher, SG, Brown, T, et al. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia. Psychiatr Serv 2006;57:133–136.CrossRefPubMed
61.
Copeland, LA, Zeber, JE, Valenstein, M, et al. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry 2003;160:1817–1822.CrossRefPubMed
62.
Kelly, DL, Kreyenbuhl, J, Dixon, L, et al. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007;33:1221–1224.CrossRefPubMed
63.
Moeller, FG, Chen, YW, Steinberg, JL, et al. Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry 1995;7:167–173.CrossRefPubMed
64.
65.
Haddy, TB, Rana, SR, and Castro, O. Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 1999;133:15–22.CrossRefPubMed
66.
Denic, S, Showqi, S, Klein, C, et al. Prevalence, phenotype and inheritance of benign neutropenia in Arabs. BMC Blood Disord 2009;9:3.PubMedPubMedCentral
67.
Shoenfeld, Y, Alkan, ML, Asaly, A, et al. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988;41:273–277.CrossRefPubMed
68.
Crosslin, DR, McDavid, A, Weston, N, et al. Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. Hum Genet 2012;131:639–652.CrossRefPubMed
69.
Paz, Z, Nails, M, and Ziv, E. The genetics of benign neutropenia. Isr Med Assoc J 2011;13:625–629.PubMed
70.
Nalls, MA, Wilson, JG, Patterson, NJ, et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am J Hum Genet 2008;82:81–87.CrossRefPubMedPubMedCentral
71.
Abecasis, GR, Altshuler, D, Auton, A, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061–1073.CrossRefPubMed
72.
Reich, D, Nalls, MA, Kao, WH, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet 2009;5:e1000360.CrossRefPubMedPubMedCentral
73.
Thobakgale, CF and Ndung'u, T. Neutrophil counts in persons of African origin. Curr Opin Hematol 2014;21:50–57.CrossRefPubMed
74.
Patchan, KM, Richardson, C, Vyas, G, et al. The risk of suicide after clozapine discontinuation: Cause for concern. Ann Clin Psychiatry 2015;27:253–256.PubMedPubMedCentral
75.
76.
Borison, RL, Diamond, BI, Sinha, D, et al. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988;24:260–263.PubMed
77.
Shiovitz, TM, Welke, TL, Tigel, PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591–595.CrossRefPubMed
Metadata
Title
Clozapine in Reducing Aggression and Violence in Forensic Populations
Authors
Kathleen Patchan
Gopal Vyas
Ann L. Hackman
Marie Mackowick
Charles M. Richardson
Raymond C. Love
Ikwunga Wonodi
MacKenzie A. Sayer
Matthew Glassman
Stephanie Feldman
Deanna L. Kelly
Publication date
01-03-2018
Publisher
Springer US
Published in
Psychiatric Quarterly / Issue 1/2018
Print ISSN: 0033-2720
Electronic ISSN: 1573-6709
DOI
https://doi.org/10.1007/s11126-017-9521-z

Other articles of this Issue 1/2018

Psychiatric Quarterly 1/2018 Go to the issue

Original Paper

Minimal Clinically Important Differences (MCID) in Assessing Outcomes of Post-Traumatic Stress Disorder

Original Paper

Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia

Original Paper

Establishing an Integrated Health Care Clinic in a Community Mental Health Center: Lessons Learned

Original Paper

Social Workers’ Perceptions of the Association Between Role Playing Games and Psychopathology

Original Paper

Factors Associated with Length of Stay in Psychiatric Inpatient Services in London, UK

Original Paper

Elder Mistreatment Perpetrators with Substance Abuse and/or Mental Health Conditions: Results from the National Elder Mistreatment Study